A novel blood-based assay for treatment monitoring of tuberculosis
Abstract
A novel 3-gene host transcriptional signature (GBP5, DUSP3 and KLF2) has been validated for tuberculosis (TB) treatment monitoring using laboratory-based RNA sequencing platforms. The signature was recently translated by Cepheid into a prototype cartridge-based test that can be run on the GeneXpert instrument. In this study, we prospectively evaluated the change in the expression of the cartridge-based 3-gene signature following treatment initiation among pulmonary TB patients who were microbiologically cured at the end of treatment.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 30, 2021
- Source ID
- 10.1186/s13104-021-05663-z
Entities
People
- Alexandra J. Zimmer
- Anna Mantsoki
- Claudia Denkinger
- David H. Persing
- Devasena Gnanashanmugam
- Erik Södersten
- Jacqueline Prieto
- Linda Strömqvist Meuzelaar
- Morten Ruhwald
- Purvesh Khatri
- Romain Wyss
- Samuel G Schumacher
- Sara Banderby
- Stefano Ongarello
Organizations
- Department for International Development
- Department of Foreign Affairs and Trade
- Dr. Ralph and Marian Falk Medical Research Trust
- Gates Foundation
- Ministry of Foreign Affairs of the Netherlands
- United States Department of Defense